A novel Trojan-horse targeting strategy to reduce the non-specific uptake of nanocarriers by non-cancerous cells

Shen, Zheyu; Wu, Hao; Yang, Su‐Geun; Ma, Xuehua; Li, Zihou; Tan, Mingqian; Wu, Aiguo

doi:10.1016/j.biomaterials.2015.08.022

Cited by 50 publications

(32 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anti-proliferative activity of ETP in different formulations was evaluated by the MTT assay using the human breast carcinoma cell line MCF-7, which expresses high levels of folate receptors [34,38]. In Figure 7B, ETP-Cubs demonstrated a significantly superior cytotoxicity compared with free drug.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Folic Acid-Targeted Etoposide Cubosomes for Theranostic Application of Cancer Cell Imaging and Therapy

Tian

Zhu

et al. 2017

Med Sci Monit

View full text Add to dashboard Cite

BackgroundThe aim of this study was to develop a novel Poloxamer-based drug delivery system featuring a tumor-targeting folate moiety, which was expected to provide better targeting properties and therapeutic effects compared with the traditional cubosomes (Cubs).Material/MethodsBoth folate-modified Cubs containing etoposide (ETP-Cubs-FA) and normal cubic nanoparticles loaded with etoposide (ETP-Cubs) were prepared through the fragmentation of bulk gels under the homogenization condition of 1500 bar, and a mean particle size of around 180 nm was obtained with a narrow size distribution. The cubosomes were further characterized by differential scanning calorimetry (DSC) and Polarized light microscopy (PLM). The release of ETP in vitro from these nanoparticles was found to be 82.5% at 36 h, showing a sustained release property compared with the free drug administration.ResultsFolate-modified cubosomes exhibited best anti-proliferative activity followed by normal cubosomes and the free drug. A further cell uptake study of Rhodamine B-loaded Cubs-FA (Rh-B-Cubs-FA) showed a marked increase of cellular accumulation compared with free Rh-B and Rh-B-loaded Cubs (Rh-B-Cubs). In vivo Rh-B-based tumor imaging demonstrated that Cubs-FA specifically targeted the tumor tissue.ConclusionsThe folate-modified cubosomes containing ETP may be a promising drug candidate for antitumor treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

“…For qualitative analysis of the cellular uptake in this study, the internalized nanoparticles in MCF-7 cells were measured [34]. Rh-B-Cubs-FA were prepared in the same way as preparing ETP-Cubs-FA.…”

Section: Methodsmentioning

confidence: 99%

Folic Acid-Targeted Etoposide Cubosomes for Theranostic Application of Cancer Cell Imaging and Therapy

Tian

Zhu

et al. 2017

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…enhanced permeability and retention (EPR) effect). [71,72] The nanomaterials can also be functionalized with active targeting ability by conjugation of targeted molecules (antibodies or ligands). [73–75] 2) The large hydrodynamic size (> 6 nm) of the nanomaterials can reduce the renal clearance, prolong the circulating half-life in blood, and enhance the accumulation at tumor sites.…”

Section: Conclusion and Future Prospectivementioning

confidence: 99%

Emerging Strategies of Cancer Therapy Based on Ferroptosis

et al. 2018

Self Cite

View full text Add to dashboard Cite

Ferroptosis, a new form of regulated cell death that is iron- and reactive oxygen species dependent, has attracted much attention in the research communities of biochemistry, oncology, and especially material sciences. Since the first demonstration in 2012, a series of strategies have been developed to induce ferroptosis of cancer cells, including the use of nanomaterials, clinical drugs, experimental compounds, and genes. A plethora of research work has outlined the blueprint of ferroptosis as a new option for cancer therapy. However, the published ferroptosis-related reviews have mainly focused on the mechanisms and pathways of ferroptosis, which motivated this contribution to bridge the gap between biological significance and material design. Therefore, it is timely to summarize the previous efforts on the emerging strategies for inducing ferroptosis and shed light on future directions for using such a tool to fight against cancer. Here, the current strategies of cancer therapy based on ferroptosis will be elaborated, the design considerations and the advantages and limitations are highlighted, and finally a future perspective on this emerging field is given.

show abstract

“…Magnetic resonance imaging (MRI) is well‐known as a clinical diagnosis tool for soft‐tissue injuries and diseases . Currently, 40–50% of clinical MRI examinations have used contrast agents to enhance the sensitivity, especially for diagnosis of tumors . On the market, there are two kinds of contrast agents for MRI, i.e., T 1 ‐ or T 2 ‐weighted contrast agents.…”

Section: R1 and R2 Measured Using Different Mri Scanner Systemsmentioning

confidence: 99%

Exceedingly Small Gadolinium Oxide Nanoparticles with Remarkable Relaxivities for Magnetic Resonance Imaging of Tumors

Shen

Fan

Yáng

et al. 2019

Small

Self Cite

View full text Add to dashboard Cite

Gd chelates have occupied most of the market of magnetic resonance imaging (MRI) contrast agents for decades. However, there have been some problems (nephrotoxicity, non‐specificity, and low r1) that limit their applications. Herein, a wet‐chemical method is proposed for facile synthesis of poly(acrylic acid) (PAA) stabilized exceedingly small gadolinium oxide nanoparticles (ES‐GON‐PAA) with an excellent water dispersibility and a size smaller than 2.0 nm, which is a powerful T1‐weighted MRI contrast agent for diagnosis of diseases due to its remarkable relaxivities (r1 = 70.2 ± 1.8 mM−1 s−1, and r2/r1 = 1.02 ± 0.03, at 1.5 T). The r1 is much higher and the r2/r1 is lower than that of the commercial Gd chelates and reported gadolinium oxide nanoparticles (GONs). Further ES‐GON‐PAA is developed with conjugation of RGD2 (RGD dimer) (i.e., ES‐GON‐PAA@RGD2) for T1‐weighted MRI of tumors that overexpress RGD receptors (i.e., integrin αvβ3). The maximum signal enhancement (ΔSNR) for T1‐weighted MRI of tumors reaches up to 372 ± 56% at 2 h post‐injection of ES‐GON‐PAA@RGD2, which is much higher than commercial Gd‐chelates (<80%). Due to the high biocompatibility and high tumor accumulation, ES‐GON‐PAA@RGD2 with remarkable relaxivities is a promising and powerful T1‐weighted MRI contrast agent.

show abstract

A novel Trojan-horse targeting strategy to reduce the non-specific uptake of nanocarriers by non-cancerous cells

Cited by 50 publications

References 35 publications

Folic Acid-Targeted Etoposide Cubosomes for Theranostic Application of Cancer Cell Imaging and Therapy

Folic Acid-Targeted Etoposide Cubosomes for Theranostic Application of Cancer Cell Imaging and Therapy

Emerging Strategies of Cancer Therapy Based on Ferroptosis

Exceedingly Small Gadolinium Oxide Nanoparticles with Remarkable Relaxivities for Magnetic Resonance Imaging of Tumors

Contact Info

Product

Resources

About